What were the main drivers of Schering-Plough's revenue growth in 2005?

The primary drivers of Schering-Plough's revenue growth in 2005 were strong performances in its Prescription Pharmaceuticals segment, particularly the cholesterol franchise products VYTORIN and ZETIA, which are marketed in partnership with Merck. Other key contributors included REMICADE, PEG-INTRON, NASONEX, TEMODAR, and the antibiotics AVELOX and CIPRO, which benefited from a full year of sales under the Bayer agreement.

What financial challenges or risks did Schering-Plough face in 2005?

Schering-Plough faced significant financial challenges including substantial litigation and investigation charges, with a $250 million increase in litigation reserves. The company was also managing the ongoing costs and operational impacts of a prior FDA Consent Decree related to manufacturing compliance. Additionally, the risk of patent expirations and generic competition for key products, as well as increasing pricing pressures from managed care organizations and government agencies, were noted as ongoing concerns.

How did the joint venture with Merck impact Schering-Plough's financial results?

The joint venture with Merck for the cholesterol products VYTORIN and ZETIA had a very positive impact on Schering-Plough's financial results in 2005. The company recognized $873 million in equity income from this joint venture, a significant increase from the prior year, reflecting strong sales growth and market penetration of these products. This joint venture was highlighted as a primary driver of the company's improved financial situation and return to profitability.

What is the company's outlook regarding Research and Development (R&D) expenses?

Schering-Plough's R&D expenses increased by 16% in 2005 to $1.9 billion, representing about 20% of net sales. The company anticipated R&D expenses to grow at a faster rate than net sales in 2006 due to the progression of its early-stage pipeline and increased clinical trial activity. A 'Development Excellence' initiative was launched to build talent and improve the R&D process.

MRK 10-K FY2005 Annual Report — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation's 2005 10-K filing reveals a significant turnaround year, with net sales increasing by 15% to $9.5 billion, driven primarily by strong performance in the Prescription Pharmaceuticals segment. This growth was largely attributed to the success of the cholesterol franchise (VYTORIN and ZETIA), developed in partnership with Merck, which captured a notable share of the market. The company also saw a return to profitability, with net income available to common shareholders of $183 million, a substantial improvement from the prior year's net loss. This recovery was achieved despite ongoing litigation charges and the lingering effects of regulatory issues, including a Consent Decree with the FDA. Management highlighted progress in its 'Action Agenda' aimed at stabilizing and improving the company's performance, marking the beginning of a 'Turnaround' phase.

Key Highlights

1Net sales increased by 15% to $9.5 billion in 2005, primarily driven by the Prescription Pharmaceuticals segment.
2The cholesterol franchise (VYTORIN and ZETIA), a joint venture with Merck, was a key growth driver, contributing significantly to sales and equity income.
3The company returned to profitability, reporting net income available to common shareholders of $183 million, a marked improvement from a net loss in 2004.
4Research and Development expenses increased by 16% to $1.9 billion, reflecting continued investment in innovation.
5Significant legal and regulatory matters, including an increase in litigation reserves by $250 million, were noted, impacting profitability.
6The company is addressing manufacturing compliance issues stemming from a previous FDA Consent Decree, with substantial progress reported.
7International operations continued to be the majority contributor to sales, accounting for 62% of total net sales.

Merck & Co., Inc. Annual Report, Year Ended Dec 31, 2005

Summary

Key Highlights

Frequently Asked Questions